Ipilimumab Plus Fotemustine Effective for Metastatic Melanoma with Brain Metastases

Share this content:

the Cancer Therapy Advisor take:

According to a new long-term analysis published in the journal Annals of Oncology, researchers have found that ipilimumab plus fotemustine continue to demonstrate efficacy in patients with metastatic melanoma at 3 years.

The NIBIT-M1 study showed that the combination demonstrated promising activity in patients with metastatic melanoma with or without brain metastases, but now researchers report the long-term efficacy of this combination.

For the study, 86 patients with metastatic melanoma, including 20 with asymptomatic brain metastases, were enrolled. Results showed that with a median follow-up of 39.9 months, the median overall survival for the whole study population was 12.9 months (95% CI: 7.1 - 18.7 months) and the 3-year survival rate was 28.5%.

For those with brain metastases, the median overall survival was 12.7 months (95% CI: 2.7 - 22.7 months) and the 3-year survival rate was 27.8%. In regard to safety, long-term immune-related adverse events consisted of G1 rush and pruritus in 21% of patients. Researchers also found that tumor BRAF-V600 mutational status did not correlate with clinical outcome.

The findings suggest that the combination of ipilimumab plus fotemustine continue to demonstrate efficacy in patients with metastatic melanoma with or without brain metastases after 3 years.

There is warranted excitement for AG-221, a drug recently granted fast track designation by the FDA.
Ipilimumab plus fotemustine continue to demonstrate efficacy in patients with metastatic melanoma at 3 years.
In the NIBIT-M1 study, the authors reported a promising activity of ipilimumab combined with fotemustine in metastatic melanoma (MM) patients with or without brain metastases. To corroborate these initial findings, they now investigated the long-term efficacy of this combination.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters